Global Risk Predictor • Private Equity Dashboard

Portfolio Heatmap

Company	Sector	Score	MOIC	Horizon
FinTech Pro Series C	FinTech	🔴 0.24	1.2x	12-18 months
MediCare+ Series B	Healthcare	🔴 0.31	1.4x	18-24 months
GreenEnergy Growth	CleanTech	🟡 0.52	1.8x	24-36 months
SaaSScale Series D	Software	🟢 0.78	3.5x	6-12 months
AutoDrive Series B	Mobility	🟢 0.85	4.2x	< 6 months

Performance Concentration

High Risk

Medium Risk

Low Risk

Total

Performance Evolution

Fund IV Performance

Top Quartile

Year 1: TVPI 1.3x

2 investments made, 1 partial exit

Year 3: TVPI 2.1x

3 exits completed, DPI 0.4x

Year 5 (target): TVPI 2.8x

Projection based on exit pipeline

FinTech Pro • Deterioration detected

Action required

M-24 → M-0 : -62% score

Deterioration detected 12 months before down round

M-18 : Growth warning

Score at 0.58, MRR growth -15%

M-6 : Down round 40% valuation

Score at 0.32, dilution anticipated

Actionable Alerts

Down round imminent detected

FinTech Pro: Score dropped from 0.85 to 0.24 in 24 months

URGENT

Exit horizon optimizable

3 companies with score >0.75 and MOIC >3x

OPPORTUNITY

Sector concentration risk

40% of portfolio in SaaS/Software

SECTORIAL

Exceptional performance detected

AutoDrive: Score 0.85, MOIC 4.2x, ready for exit

PERFORMING

Insights & Priority Actions

Urgent: Down round imminent

FinTech Pro and MediCare+ face significant dilution risk.
Corrective actions required within 3-6 months to preserve value.

⏱️ 3-6 months 💰 25% of NAV

Optimized exit pipeline

3 companies ready for exit within 12 months.
Potential realization of 3.2x average MOIC.

AutoDrive 4.2x MOIC

SaaSScale 3.5x MOIC

LogiTech 2.8x MOIC

Sector Concentration

40% of portfolio in SaaS/Software.
High exposure to tech funding cycles.

📊 Diversification recommended

Retrospective: Forecast vs Reality

The model predicts down rounds with 9-15 months lead time

TechScale (Fund III)

Signal detected at M-12 (score 0.45)
9 months before 35% down round

BioGen (Fund II)

Signal detected at M-18 (score 0.38)
15 months before FDA approval failure

PE Model Accuracy

88% detections confirmed
12 months average lead